Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 11-20

  Byakika Kibwika, Pauline ^a,b   Lamorde, Mohammed ^a,b   Mayanja Kizza, Harriet ^a   Merry, Concepta ^a,b   Colebunders, Bob ^c,d   van Geertruyden, Jean Pierre ^c,d  

^a MAKERERE UNIVERSITY   (Uganda)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Artemether lumefantrine; Effectiveness; Efficacy; Malaria; Safety

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIFAMPICIN;

ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; OTOTOXICITY; POLYMERASE CHAIN REACTION; PREGNANCY; QT PROLONGATION; REVIEW; SENSITIVITY ANALYSIS;

EID: 77950850784     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. WHO. http://wwwwhoint/mediacentre/factsheets/fs094/en/indexhtml. Accessed July 2, 2009.
2. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004;71(2):1-15.
3. WHO/CDS/RBM/2000.17. The Abuja Declaration and the Plan of Action. 2000 April 25.
4. Checchi F, Piola P, Fogg C, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: PK and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;19(5):59.
5. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrinefor outpatient treatment of malaria in Tanzanian children: a four arm randomised effectiveness trial. Lancet. 2005;365:1474-1480.
6. Ajayi IO, Browne EN, Bateganya F, et al. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar J. 2008;27(7):190.
7. WHO. World Malaria Report. Geneva: World Health Organization; 2008.
8. Omari AA, Gamble CL, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2006;19(2):CD005965.
9. Omari AA, Gamble CL, Garner P. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2005;4 (CD005564).
10. Travassos, Mark A, Laufer, et al. Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Pediatr Res. 2009;65(5):64R-70R.
11. White NJ, Van Vugt M, Ezzet F, Ezzet F. Clinical Pharmacokinetics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet. 1999;37:105-125.
12. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother. 2007;8:75-94.
13. Golenser J, Waknine JH, Krugliak M, et al. Current perspectives on the mechanisms of action of artemisinins. Int J Parasitol. 2006;36: 1427-1441.
14. Aweeka FT, German PI. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008;47(2):91-102.
15. Abdulla S, Borrmann S, D'Alessandro U, et al. Efficacy and safety of artemetherlumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet. 2008;372:1819-1827.
16. Abdulla S, Sagara I. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Malar J. 2009; 8(1):1186/475-2875-8-S1-S7.
17. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria parasites. Br J Clin Pharmacol. 1998;46:553-561.
18. White N. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates. 1998;1:3-9.
19. Djimdé A, Lefèvre G. Understanding the pharmacokinetics of Coartem®. Malar J. 2009;8(1):1186/475-2875-8-S1-S4.
20. Ezzet F, Van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697-704.
21. Ashley EA, Stepniewska K, Lindegårdh N. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrugresistant falciparum malaria. Trop Med Int Health. 2007;12:201-208.
22. Premji ZG, Abdulla S, Ogutu B, et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemetherlumefantrine: a review of the evidence. Malar J. 2008;7:244.
23. Michael Makanga SK. The clinical efficacy of artemether/lumefantrine (Coartem®). Malar J. 2009;8(1):1186/475-2875-8-S1-S5.
24. Van Vugt M, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether/lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg. 1999;60: 936-942.
25. Van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether/ lumefantrine for the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94:545-548.
26. Lefèvre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and PK trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 2001;64(5-6):247-256.
27. Hatz C, Soto J, Nothdurft HD, et al. Treatment of acute uncomplicated falciparum malaria with artemether/lumefantrine in nonimmune populations: a safety, efficacy and PK study. Am J Trop Med Hyg. 2008;78:241-247.
28. Rojanawatsirivej C, Vijaykadga S, Amklad I, et al. Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 2003; 34:536-541.
29. Bukirwa H, Yeka A, Kamya MR, et al. Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria in Uganda. PLos Clin Trials. 2006;1 (1):0010007.
30. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children. JAMA. 2007;297:2210-2219.
31. Gürkov R, Eshetu T, Miranda IB, et al. Ototoxicity of artemether/ lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J. 2008;7:179.
32. Kabanywanyi AM, Mwita A, Sumari D, et al. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J. 2007;6:146.
33. Kamya MR Yeka A, Bukirwa H, et al. Artemether/lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2:e20.
34. Mårtensson A, Strömberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether/lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005;41:1079-1087.
35. Mårtensson A, Ngasala B, Ursing J, et al. Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect Dis. 2007;195:597-601.
36. Mohamed AO, Eltaib EH, Ahmed OA, et al. The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether/lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan. Ann Trop Med Parasitol. 2006;100:5-10.
37. Mukhtar EA, Gadalla NB, El-zaki SEG, et al. A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether/lumefantrine in eastern Sudan. Malar J. 2007;6:92.
38. Yeka A, Dorsey G, Kamya MR, et al. Artemether/lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE. 2008(3): e2390.
39. Mulenga M, Van geertruyden JP, Mwananyanda L, et al. Safety and efficacy of lumefantrine-artemether (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. Malar J. 2006;5:73.
40. Toovey S. Effectiveness of co-artemether in an unsupervised outpatient setting for the treatment of falciparum malaria. Travel Med Infect Dis. 2008;6(1-2):29-31.
41. Adjei GO, Kurtzhals JA, Rodrigues OP, et al. Amodiaquine artesunate vs artemether/lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J. 2008;7:127.
42. Faye B, Ndiaye JL, Ndiaye D, et al. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J. 2007;6:80.
43. Koram KA, Abuaku B, Duah N, et al. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005;95: 194-203.
44. Meremikwu M, Alaribe A, Ejemot R, et al. Artemether/lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J. 2006;5:43.
45. Owusu-Agyei S, Asante KP, Owusu R, et al. An open label, randomised trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone and artemether/lumefantrine for the treatment of uncomplicated malaria. PLoS ONE. 2008;3:e2530.
46. Sagara I, Dicko A, Djimde A, et al. A randomized trial of artesunate-sulfamethoxypyrazinepyrimethamine versus artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2006;75:630-636.
47. Sowunmi A, Gbotosho GO, Happi CT, et al. Therapeutic efficacy and effects of artemether/lumefantrine and amodiaquine-sulfalenepyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. Am J Trop Med Hyg. 2007;77:235-241.
48. Sutherland CJ, Ord R, Dunyo S, et al. Reduction of malaria transmission to Anopheles mosquitoes with a sixdose regimen of co-artemether. PLoS Med. 2005;2:e92.
49. Zongo I, Dorsey G, Rouamba N, et al. Artemether/lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomized non-inferiority trial. Lancet. 2007;369:491-498.
50. Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether/lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis. 2007;45:1453-1461.
51. Fanello CI, Karema C, van Doren W, et al. A randomised trial to assess the safety and efficacy of artemether/lumefantrine (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Trans R Soc Trop Med Hyg. 2007;101:344-350.
52. Guthmann JP Cohuet S, Rigutto C, et al. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg. 2006;75:143-145.
53. Ndayiragije A, Niyungeko D, Karenzo J, et al. Efficacité de combinaisons thérapeutiques avec des dérivés de l'artémisinine dans le traitement de l'accès palustre noncomplique au Burundi. Trop Med Int Health. 2004;9:673-679.
54. Van den Broek I, Kitz C, Al Attas S, et al. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J. 2006;5:113.
55. Krudsood S, Chalermrut K, Pengruksa C, et al. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP®) and artemether/lumefantrine Coartem®/ Riamet®) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 2003;34: 316-321.
56. Stohrer JM, Dittrich S, Thongpaseuth V, et al. Therapeutic efficacy of artemether/lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic. Trop Med Int Health. 2004;9:1175-1183.
57. Mayxay M, Khanthavong M, Lindegårdh N, et al. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether/lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin Infect Dis. 2004;39:1139-1147.
58. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757-765.
59. Hutagalung R, Paiphun L, Ashley EA, et al. A randomized trial of artemether/lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malar J. 2005;4:46.
60. Van den Broek IV, Maung UA, Peters A, et al. Efficacy of chloroquine + sulfadoxine-pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh. Trans R Soc Trop Med Hyg. 2005;99:727-735.
61. Haque R, Thriemer K, Wang Z, et al. Therapeutic efficacy of artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh. Am J Trop Med Hyg. 2007;76:39-41.
62. Thapa S, Hollander J, Linehan M, et al. Comparison of artemether/ lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Eastern Nepal. Am J Trop Med Hyg. 2007;77:423-430.
63. Jansen FH, Lesaffre E, Penali LK, et al. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. Am J Trop Med Hyg. 2007(77):1005-1009.
64. Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005;365(9469):1467-1473.
65. Achan J, Tibenderana J, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ. 2009;339(2763):2763.
66. Falade C, Makanga M, Premji Z, et al. Efficacy and safety of artemether/ lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005(99):459-467.
67. Falade C, Manyando C. Safety profile of Coartem®: the evidence base. Malar J. 2009;8 Suppl 1:S6.
68. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with coartemether. Trans R Soc Trop Med Hyg. 2004;98:261-267.
69. Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N Engl J Med. 1997;336:1328.
70. Cousin M, Kummerer S, Lefèvre G, et al. Advisory Committee Briefing Book. Coartem® (artemether/lumefantrine) tablets for the treatment of malaria in patients with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum. http://wwwfdagov/ohrms/dockets/ac/08/briefing/2008-4388b1-02-Novartispdf. 2008.
71. Bakshi R, Hermeling-Fritz I, Gathmann I, et al. An integrated assessment of the clinical safety of artemether-lumefantrine:a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 2000;94:419-424.
72. Nankabirwa Zurovac D, Njogu JN, et al. Malaria misdiagnosis in Uganda-implications for policy change. Malar J. 2009;16(8):66.
73. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J. 2006;5:50.
74. Barnes KI, Little F, Smith PJ, et al. Sulfadoxine-pyrimethamine PKs in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006; 80:582-596.
75. Price RN, Hasugian AR, Ratcliff A, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisininpiperaquine for drug-resistant malaria. Antimicrob Agents Chemother. 2007;51:4090-4097.
76. ter Kuile FO, Terlouw DJ, Kariuki SK, et al. Impact of permethrin-treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya. Am J Trop Med Hyg. 2003;68:68-77.
77. Slutsker L, Taylor TE, Wirima JJ, et al. In-hospital morbidity and mortality due to malaria-associated severe anaemia in two areas of Malawi with different patterns of malaria infection. Trans R Soc Trop Med Hyg. 1994;88:548-551.
78. Schellenberg D, Menendez C, Kahigwa E, et al. African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Am J Trop Med Hyg. 1999;61:431-438.
79. Nosten F, White NJ. Artemisinin-based combination treatment of Falciparum malaria. Am J Trop Med Hyg. 2007;77(6):181-192.
80. Longo M, Zanoncelli S, Manera D, et al. Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol. 2006;21(1):83-93.
81. Dellicour S, O ter Kuile F, Stergachis A. Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med. 2008;5(9):187.
82. Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. Lancet Infect Dis. 2007;7(2):118-125.
83. McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrugresistant Plasmodium falciparum. Clin Infect Dis. 2001;33(12):2009-2016.
84. Dellicour S, Hall S, Chandramohan D. The safety of artemisinins during pregnancy: a pressing question. Malar J. 2007;14(6):15.
85. Adam I, Elhassan EM, Omer EM, Abdulla MA. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann Trop Med Parasitol. 2009;103(3):205-210.
86. Manyando C, Mkandawire R, Puma L, et al. Safety profile artemetherlumefantrine (AL; Coartem®) compared sulfadoxine-pyrimethamine (SP) pregnant women symptomatic malaria: preliminary results of an observational study. Abstract 570, 57th Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), New Orleans, Louisiana, USA, December 2008.
87. Tarning J, McGready R, Lindegardh N, et al. Population PKs of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated P. falciparum malaria. Antimicrob Agents Chemother. 2009;53:3837-3846.
88. McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62(12): 1021-1031.
89. McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;23(5):e253.
90. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet. 2000;356(9235): 1051-1056.
91. French N, Nakiyingi J, Lugada E, et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS. 2001;15(7):899-906.
92. Francesconi P, Fabiani M, Dente MG, et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS. 2001;15(18):2445-2450.
93. Atzori C, Bruno A, Chichino G, et al. HIV-1 and parasitic infections in rural Tanzania. Ann Trop Med Parasitol. 1993;87(6):585-593.
94. Van Eijk AM, Ayisi JG, Ter Kuile FO, et al. HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS. 2003;17(4):595-603.
95. Verhoeff FH, Brabin BJ, Hart CA, et al. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health. 1999;4(1):5-12.
96. Steketee RW, Wirima JJ, Slutsker L, et al. Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Am J Trop Med Hyg. 1996;55(1):17-23.
97. Shulman. Importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg. 2003;97(1):30-35.
98. Bloland PB, Wirima JJSR, Chilima B, et al. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS. 1995;9(7):721-726.
99. Byakika-Kibwika P, Ddumba E, Kamya M. Effect of HIV-1 infection on malaria treatment outcome in Ugandan patients. African Health Sciences. 2007;7(2):86-92.
100. Kamya MR, Kigonya CN, McFarland W. HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children. AIDS. 2001;15(9):1187-1188.
101. Kamya MR, Gasasira AF, Yeka A, et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis. 2006;193(1):9-15.
102. Colebunders R, Bahwe Y, Nekwei W, et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire. J Infect Dis. 1990;21(2):167-173.
103. Van Geertruyden JP, Mulenga M, Mwananyanda L, et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis. 2006;194(7): 917-925.
104. Birku YME, Björkman A, Wolday D. Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection treated with artemisinin. Ethiop Med J. 2002;1:17-26.
105. Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis. 2005;192:984-991.
106. Van Geertruyden JP, Mulenga M, Kasongo W, et al. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr. 2006;43(3):363-367.
107. Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS. 2005;19(10):995-1005.
108. Moses R. Kamya, Adoke Yeka, Hasfa Bukirwa, et al. Artemetherlumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2(5):1371.
109. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children follwoing treatment with artesunate for uncomplicated malaria in Uganda. CID. 2008;46:985-991.
110. German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects PK exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009;51(4):424-429.
111. Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother. 2008;62(5):872-878.
112. Lefevre G. PK and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2002;54:485-492.
113. Bloland PB. Drug resistance in malaria. WHO/CDS/CSR/DRS/20014. 2001.
114. Huong NM, Hweitt S, Davis TM. Resistance of P. falciparum to antimalarial drugs in a highly endemic area in southern Viet Nam: a study in vivo and vitro. Trans R Soc Trop Med Hyg. 2001;95:325-329.
115. Yang H, Liu D, Yang Y. Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Trans R Soc Trop Med Hyg. 2003;97:226-228.
116. Gordon P, Kelly R, Hedderwick S. Failure of artemether-lumefantrine (Riamet) to clear Plasmodium falciparum in non immune traveller. Abstract. First Interanational Conference of Travel Medicine and Infectious Disease, London, UK. 2005.
117. Yangsutaka Mizuno, Yasuyuki Kato, Koichiro Kudo, et al. First case of Treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria. Jpn J Infect Dis. 2009; 62:139-141.
118. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemetherlumefantrine (Coartem). J Infect Dis. 2005;191:1014-1017.
119. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M. Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000;108: 13-23.
120. Newton PN, Fernandez FM, Plancon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med. 2008;5:e32.
121. Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health. 2007;12:68-74.
122. Bate R, Coticelli P, Tren R. Antimalarial drug quality in the most severely malarious parts of Africa-a six country study. PLoS ONE. 2008;3:e2132.